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SUMMARY 
In the sera of ten normal humans and twenty-eight candidates for organ trans-
plantation, the passive haemagglutination test detected a 50% incidence of 
preformed antibodies of low titre directed against horse serum. Such antibodies 
were also found to cross react with goat or rabbit sera in most instances. Seventeen 
of the organ recipients were later studied after the institution of treatment with 
horse antihuman-lymphocyte globulin (ALG). The incidence of anti-horse-serum 
antibodies rose to 100%. At the same time, an increased activity against goat 
serum developed; cross-reactions against rabbit serum were also demonstrated but 
to a less pronounced degree. With immunoelectrophoresis and Ouchterlony 
diffusion tests, it was shown that the cross-reactivity was to similar although not 
necessarily identical protein components of the different heterologous sera. 
These data suggest that there is an inherent risk in switching from one ALG 
to another, particularly if horse and goat derivatives are used sequentially. Since 
rabbit ALG does not cross react so extensively with horse or goat serum it would 
be predicted to be a relatively safer second-line agent. 
These expectations seemed to have been realized in six patients who were given 
more than one kind of ALG, always beginning with horse globulin. When goat 
ALG was administered second, anaphylactic reactions tended to appear early, but 
when the rabbit product was given second or third, it was relatively well tolerated. 
INTRODUCTION 
In the initial transplantation trials with horse anti-human-Iymphocyte globulin (ALG), this 
agent was administered in combination with azathioprine and prednisone and its use limited 
to a maximum of four post-operative months (Starzl et al., 1967). It soon became clear, 
particularly after transplantation between non-related individuals, that an 'escape' from 
immunosuppressive control often occurred after the discontinuance of the intramuscular 
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globulin injections (Starz!, 1969; Starzl et at., 1969). Unfortunately, prolongation of the 
treatment course was often prevented in subsequent cases by the development of toxic 
reactions to the horse ALG being given. As a consequence, ALG prepared from the serum 
of immunized rabbits and goats was substituted for the equine globulin on a number of 
occasions (Starzl, 1969; Starzl et at., 1969). 
It is the purpose of this report to comment upon the degree of safety with which a switch 
may be made from one heterologous serum donor to another, based on observations in a 
number of cases in which this was actually done. In addition, immunological data will be 
presented about the cross-reactivity of horse, rabbit and goat ALG. The latter studies were 
carried out with the passive hemagglutination method, Ouchterlony analysis and immuno-
electrophoresis. 
METHODS 
Clinical cases 
Three recipients of livers and three recipients of kidneys were initially treated with horse 
ALG. Nine to 119 days later, the treatment was stopped, either because of suspected 
anaphylactic reactions (four examples), because of severe reactions at the intramuscular 
injection sites (one example), or because the end of an arbitrary treatment period had been 
reached (one example). Therapy with azathioprine and prednisone was continued without 
interruption. 
Administration of goat ALG was instituted without delay in four cases. In two others, 
rabbit globulin was started after intervals of 67 and 75 days. Finally, five patients received 
globulin from all three species, the horse product always being the first. In three cases the 
goat derivative was used next and in the other two the rabbit ALG was used as the second 
agent. The data from these cases are summarized in Table 1. 
Passil'e haemaggiutination 
This examination was the most sensitive one used. In principle, it involves the detection of 
antibodies in test sera by their ability to cause agglutination of chromic chloride treated 0 
negative human red cells that have been coated with heterologous protein to make a complex 
antigen (Gold & Fudenberg, 1967). 
Preparation of antigen. The red cells were coated with the sera of ten different humans, as 
well as with sera from one horse, one goat and one rabbit. Before mixing with the red cells, 
the sera were inactivated at 56°C for 30 min, diluted ten-fold with normal saline solution, and 
added to an equal volume of 0·1 % chromic chloride in saline. The solution was then added 
to an equal volume of packed red cells, incubated at room temperature for 5 min, and the 
mixture washed four times with saline. The coated cells were separated by centrifugation 
and resuspended in normal saline solution in a 1 % concentration by volume. 
Measure of cross-reactivity with specific antisera. The different varieties of coated human 
red cells were exposed to the following commercial antisera (Hyland Laboratories, Los 
Angeles, California): (1) rabbit antiserum raised against human serum, (2) rabbit antiserum 
raised against horse serum, (3) rabbit antiserum raised against goat serum, and (4) goat 
antiserum raised against rabbit serum. When reacted against normal serum from the donor 
species, the four commercial antisera defined a minimum of eleven, eight, ten and eleven 
precipitin bands, respectively. To 0·025 ml of serial two-fold dilutions of the commercial 
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antisera were added equal aliquots of the coated cellsuspensions. Following incubation at 
4 'C for 18 hr, the cells in the micro-plate wells were viewed grossly; the end point was said to 
be the greatest dilution of antisera causing visible agglutination. 
Detection of and cross-reactivity of naturally occurring antibodies. Using exactly the same 
technique, it was determined if the agglutination described in the above section could be 
caused by the normal serum of the different species. For example, red cells coated with horse 
serum were mixed with normal human, goat and rabbit serum; the red cells coated with 
rabbit serum were exposed to the serum of humans, a goat and a horse, etc. 
The search for natural antibodies in humans was a very complete one. The sera examined 
were obtained from ten healthy donors as well as from twenty-eight patients who ultimately 
received renal, hepatic, splenic or cardiac homografts. In each case, it was determined if the 
patient serum was capable of agglutinating red cells coated with horse, rabbit, or goat 
protein, and if so to what titre. 
The measurement of antibodies induced by ALG therapy. Using the same method, antibodies 
against all three heterologous serum proteins were repeatedly sought before and at varying 
intervals after the institution of ALG therapy in twenty-one cases. Sixteen of the renal 
recipients were treated with horse globulin only and one other was administered horse and 
goat ALG in that order. The four other patients had orthotopic liver transplantation. 
One had horse ALG only, but the other three were given globulin from all three species. In 
all recipients, azathioprine and prednisone were begun shortly before or at the time of 
transplantation and continued indefinitely in varying doses (Starzl, 1969; Starzl et aI., ] 967). 
Immunoelectrophoresis 
Although exquisitely sensitive, the passive haemagglutination method did not allow 
identification of the individual protein components against which antibodies were directed. 
For this purpose and also to confirm the findings obtained with passive haemagglutination, 
serum samples were also subjected to immunoelectrophoresis (Scheiddegger, 1955). The 
25 x 75 mm microelectrophoretic slide was coated with 2 ml of 0·1 g/lOO ml agar gel in 
pH 8·6 veronal buffer. The centre (antigen) well was charged with 0·001 ml of a 1: 1 dilution 
of normal senlm obtained from the human, horse, goat and rabbit. Following electro-
phoresis for 90 min at 5 V/cm of gel potential difference, the peripheral troughs were filled 
with 0·07 ml of patient sera or commercial antisera, also in a 1: 1 dilution. Immunodiffusion 
was allowed to continue at 4cC for 2-3 days. ' 
Commercial antisera. The same commercial antisera used for the passive haemagglutina-
tion test (see earlier section) were placed in the trough. Thus, the normal serum of the human, 
horse, goat and rabbit was interacted with antisera raised in the rabbit or goat against these 
species. Cross reactivity was considered to be present when the different heterologous anti-
sera produced precipitin bands in the same location. 
Patient sera. Exactly the same examination was carried out except that the 'antisera' 
were from the patients who had received ALG prepared from one or more species. 
Ouchter/ony double diffusion 
Sera from seventeen patients recelvmg horse ALG only were further examined for 
cross-reactivity with horse, goat and rabbit sera using a standard micro-Ouchterlony method 
(Ouchterlony, 1,958). The patients' serum was placed in the centre well and the heterologous 
" 
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sera in the three peripheral wells; the volume of serum in each well was 0·01 ml. Lines of 
fusion between adjacent bands indicated the presence of identically reacting protein frac-
tions. 
RESULTS 
Clinical observations 
Six patients had a change in ALG from a few days to many months after the institution of 
equine globulin therapy (Table 1). Immediate serious difficulties were not caused by the 
second ALG but in two cases in which the switch was from horse to goat globulin, reactions 
after 15 days necessitated a further switch to the rabbit. 
Cross-reactivity as studied with specific antisera 
Apparent interspecies cross-reactivity was demonstrated with antisera raised against the 
serum of the human, horse, goat and rabbit (Table 2). Using the passive haemagglutination 
method, the most powerful cross-species reaction of each of the animal antisera was with 
human serum. However, there were also cross-reactions to a less pronounced degree within 
the circle of the three animals. For example, the anti-equine serum antibodies agglutinated 
red cells coated with horse serum to a titre of I: 128,000; when the red cells were covered 
with goat protein the titre was 1: 256. The same thing was seen with variations in all inter-
species combinations tested (Table 2). 
TADLE 2. Cross-reactivity of specific commercial antisera with normal human, horse, goat and rabbit serum 
Antigen Specific antisera 
Human Rabbit anti-human-serum 
serum Rabbit anti-horse-serum 
Rabbit anti-goat-serum 
Goat anti-rabbit-serulll 
Horse Rabbit anti-human-serum 
serum Rabbit-anti-horse-serum 
Rabbit anti-goat-serum 
Goat anti-rabbit-serum 
Goat Rabbit anti-human-serum 
serum Rabbit anti-horse-serum 
Rabbit anti-goat-serum 
Goat anti-rabbit-serum 
Rabbit Rabbit anti-human-serum 
serum Rabbit anti-horse-serum 
Rabbit anti-goat-serum 
Goat anti-rabbit-serum 
Passive 
Serum protein components identified by 
immunoelectrophoresis 
haemagglutination ------------------
titre* Additional 
Albumin at a2 M yM yA yG fractions 
1: 8,000,000 + + + + + + + 
1 : 8,000,000 ± + 
1 :4,000,000 + + + 
1 : 4,000,000 + + + + 
1 :256,000 + ± + 
1: 128,000 + + + + + + + 
1 :256 + + + + 
1 :256 + + 
1 :4,000 + + + 
1 :256 + + + 
1: 1,000,000 + + + + + + + 
No reaction 
1:32 
No reaction 
No reaction 
1 :256,000 + + + + + + + 
The titres given were determined by the passive haemagglutination method. The individual serum protein 
fractions reacting with the antisera were identified by immunoelectrophoresis . 
... The titre is expressed a~ the reciprocal of the greatest dilution of antisera giving visible agglutination. 
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With immunoelectrophoresis, it was found that the protein components responsible for 
the interspecies cross-reactivity were widespread (Table 2). They included the albumin, 
yG-globulin and especially the macroglobulins. 
Naturally occurring antibodies against sera of other species 
No naturally occurring antibodies could be detected in the serum of the normal horse, 
goat or rabbit which were directed against the serum of the other two members of the animal 
group. 
However, there were antibodies in all three animal species which reacted against the serum 
of some members of the ten man normal human panel. The horse, goat and rabbit sera 
caused low titre (1: 16 to 1 :256) agglutination in five out often, seven out often and one out 
of ten of the human sera, respectively. 
TABLE 3. Frequency of naturally occurring antibodies against normal horse, goat or rabbit serum in 
twenty-eight pretransplantation patients who had not received ALG and in ten normal donors 
Pre-transplant Normal donor Total Per cent 
Patients showing no reactions 7/28 2/10 9/38 23·6 
Patients reacting against a single species 
Horse 0 1 2·7 
Goat 6 3 9 23·7 
Rabbit 0 0 0 0 
Total 6/28 4/10 10/38 26·4 
Patients reacting against two species 
Horse and goat 4 3 7 18·2 
Horse and rabbit 1 0 1 2·7 
Goat and rabbit 1 0 1 2·7 
Total 6/28 3/10 9/38 23-6 
Patients reacting against three species 9/28 1/10 10/38 26·4 
Total positive reactions 21/28 8110 29/38 76'4% 
A positive reaction was defined as a titre of 1; 2 or greater by the passive haemagglutination 
method. 
Testing in the other direction, the sera of the ten normal humans mentioned above as well 
as sera from twenty-eight transplant candidates very often contained antibodies against 
normal horse, goat or rabbit serum or some combination of these sera (Table 3). The 
magnitude of the titres is summarized in Fig. 1. The range of the agglutinating ability was 
1 :2 to 1 :2048; there were eight examples of titres of 1: 256 or greater. 
Antibodies in the sera of ALG treated patients 
Incidence. As already mentioned, there were a number of patients who had antibodies 
against equine, rabbit or goat serum before receiving treatment with horse ALG; the titres 
were usually quite low (Fig. 2). From I to 4 weeks after the institution of horse ALG there 
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were sharp increases in the anti-horse-serum antibodies in all of seventeen cases (Fig. 2). In 
rough parallel with these changes were coincident rises in the activity against both normal 
goat and rabbit serum, particularly the former (Fig. 2). 
Five other patients wcre first treated with horse ALG and subsequently with goat and 
rabbit globulin; a sixth patient received secondary therapy only with the goat product. At 
the outset the changes were as shown in Fig. 2. With the switch to another heterologous 
globulin, all three titres tended to rise even farther but did not undergo any distinctive 
subsequent alteration in relation to each other. 
<II 8 
1: 
OJ 
15 6 
0. 
! 4 
z 
2 
o 
19 patients f;:J 26 potients 
(a) 
Passive haemagg lutinatian titre 
FIG. 1. Distribution curves of naturally occurring anti-horse (a), anti-goat (b) and anti-rabbit 
(c) antibody titres in the sera of thirty-eight patients who had not received ALG. The titres were 
quantitated by the passive haemagglutination method and expressed as the reciprocal of the 
greatest dilution of serum giving visible agglutination. 
Cross-reactivity. The foregoing results suggested that the administration of horse ALG 
to patients caused antibodies to develop not only against equine protein but often against 
goat and rabbit proteins as well. 
With immunoelectrophoresis it was determined to which constituents of the heterologous 
sera the human antibody response was directed in five patients who had been given only 
horse ALG. The results are summarized in Fig. 3. The antibodies evoked by the horse 
globulin had the greatest avidity to the same protein constituents in normal horse, goat and 
rabbit serum. The first antibodies to appear were usually directed against 'VA-globulin; later 
the macroglobulins were a favourite target. 
The Ouchterlony analysis was used in sixteen sera from patients treated only with horse 
ALG to determine further if the cross-reactivity were to identical protein constituents. 
Fusion of the terminal precipitin lines could be demonstrated in only one instance; the 
reactions against the horse, rabbit and goat sera were to identical protein components. In 
the other fifteen cases, identity could not be proved but in seven of these the relative insensi-
tivity of the method resulted in no precipitin bands at all being seen even at the horse serum 
interface. In several more instances, precipitin bands were absent at the goat and rabbit 
interfaces, despite the fact that anti-horse, anti-goat and anti-rabbit antibodies had been 
demonstrated to be present by the other more sensitive techniques. 
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DISCUSSION 
One of the most interesting findings in this study was the presence of preformed anti-
animal-serum antibodies in so many patients who had not been exposed to ALG. The 
explanation for this kind of low titre activity can only be speculated upon. There may have 
been naturally occurring heterospecific antibodies. It is also conceivable that immunization 
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1:256 
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1:64,000 
/'/6,000 
1:4000 
1:1024 -
1,256 
1:64 
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1:64,000 
1:16,000 
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I fffflif~ ~ . __ 
( b) 
(c) 
fDID~~~ f1gflu~f~gf~l 
I 2 3 4 5 6 7 8 9 10 II 12 13 14 IS 16 17 
FIG. 2. Elevations in anti-horse- (a), anti-goat- (b) and anti-rabbit-serum (c) antibody titres 
occurring during the period of horse ALG administration in seventeen recipients of kidney or 
liver homografts. The antibody levels were quantitated by the passive haemagglutination 
method. The titres before treatment (.) and the maximum titres (0) attained are given for each 
patient. 
at some time in the distant past with one of the widely employed animal biological products 
could have been responsible. The latter explanation has been suggested (Arbesman et al., 
1960) to account for a very high incidence of horse protein sensitization in a clinic population 
in the United States. 
Whatever the explanation, more than 70% of the individuals amongst our normal volun-
teers and transplant candidates had antibodies against horse, goat or rabbit proteins. In 
many of these cases, the pre-existing antibodies reacted against the serum of two of the three 
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or even all three animal species. After horse ALG had been started the incidence of anti-
equine-serum antibodies became 100%. Moreover, the administration of horse ALG 
proved to be a highly effective way of also inducing antibodies reacting with both goat and 
rabbit serum, particularly the former. Without exception, the appearance of rising titres of 
anti-equine activity was accompanied by closely correlated increases in antigoat reactivity. 
Incidental sensitization to rabbit protein also occurred but not so consistently and'to a lesser 
extent. 
Time (weeks) 
Normal 0 5 10 15 20 25 30 35 40 
serum ~:~ I ! ALG 11 C~se Horse II II II • • 1 ~ 2 Goat yA I ! II r I II I I II • I q II 
Rabbil II Ii II II I I I f I I I I· II 
~Aid~ 
Case Horse o~I~ I ! 1+1 
• 
I I I ~ ~ ~ 
e Goat :: : I :: I ~ : : : : : : : : : Rabbit 
~Aid 60 
Case 
Horse 
·;U I ~ ~ ~ I Ii I I I 
II Goal r:. 1 i II • • • .: • • I I 
Rabbit K;~ I i w • Ii • .; I • I I ~Aid
~:f Case Horse o;I~ I ! ~ e I I 
13 Goat II j I 
":1' II I I 
Rabbit Ii II I':!' II I I 
Aid~ ~Aid_ 
Horse °f~ I ! IIII ~1 ~ ~~ ~ ~f I • I Case 14 Goat 
'Ii I ! IIII II; II II! 111M n • n Rabbit ]'A I I i" I II II 1 I: II .. W - I I 
FIG. 3. Immunoelectrophoretic analysis of sequential sera from patients receiving only horse 
ALG. Each patient serum sample was reacted against normal horse, goat and rabbit sera, 
Protein components interacting with a given test semm are indicated by a solid square; an open 
square represents a negative test. The duration of ALG therapy is given for each case. yA, 
lA-Globulin; "2M, "2-macroglobulin; "t. IXl-globulin; TR, transferrin, 
It is impossible to say to what degree the widely reacting heterologous antibodies in the 
patient sera were caused by varieties of horse protein which are found in essentially identical 
forms in the goat and rabbit. The data from the Ouchterlony analysis indicated such identity 
in only one of sixteen experiments; however, this method has the deficiency of insensitivity. 
At the least, it seems certain that the cross-reactivity was explicable by antigenic similarities 
in the serum proteins of the three species and that these reacted commonly to the antibodies 
raised with the serum of one of these species. Furthermore, the magnitude of cross-reactivity 
seemed greater between the horse and goat than between the horse and rabbit, findings 
which were consistent with those reported in related kinds of immunological research 
(Heidelberger & Landsteiner, 1923; James, 1965; Nuttall, 1904). 
The development of cross-reacting heterologous antibodies in patients receiving primary 
treatment with horse ALG should be taken into consideration in planning therapy with a 
globulin from a second or third species. The data from the present study suggests on im-
munological grounds that the rabbit would be the preferred secondline heterologous serum 
donor. This expectation appeared to have been borne out in the clinical observations. Rabbit 
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ALG given as secondary or tertiary therapy did not cause any early reactions and was 
continued for 35-83 days. 
In contrast, the immunological analyses showed that sensitization to horse serum coinci-
dentally resulted in the almost parallel development of antibodies against goat protein. 
Consequently, it was not surprising that two of our three patients who were given secondary 
goat ALG developed anaphylactic reactions within 15 days which were no different than 
those caused earlier by the horse globulin. The third patient had no difficulty during many 
ensuing months. 
There are other implications to the development of cross-reacting antibodies during 
ALG therapy. If these are present in significant titres they could undermine the immuno-
suppressive efficacy of the new globulin after a switch is made from one species source to 
another. The reports of Lance (1968), Ono et al. (1969) and Jooste et aT. (1968) have all 
indicated that when immune elimination becomes sufficiently rapid, the ability ofALG to 
mitigate homograft rejection is at least partly lost. 
Both the problems of toxicity and loss of immunosuppressive efficacy should theoretically 
be minimized by the substitution of rabbit ALG in patients sensitized to horse globulin. The 
goat product could be reserved for a later time and only if an eventual return to horse globu-
lin proves impossible. If rotation could be restricted to the horse and rabbit, return to 
equine ALG might ultimately be possible since horse protein sensitization can recede 
sufficiently under immunosuppression to permit the reinstitution of horse ALG at a later 
date (Iwasaki et al., 1967; Kashiwagi et al., 1968). 
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